Wave Life Sciences’ share price has been in the doldrums since late 2019, when its Duchenne muscular dystrophy project suvodirsen crashed, followed by disappointing data with one of its Huntington’s disease assets, WVE-120102.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,